Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21059187 | 0.96 | L3MBTL1 (0.63) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL21059246 | 0.94 | L3MBTL1 (0.62) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL6954631 | 0.91 | KMT2A (0.68) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL6129365 | 0.87 | CYP1A2 (0.60) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL1516517 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL2234416 | 0.86 | GAA (0.59) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL7256757 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL10893778 | 0.84 | KMT2A (0.72) | SMN1; SMN2L3MBTL1KMT2AALDH1A1TSHR | |
| SCHEMBL5656282 | 0.84 | KMT2A (0.67) | CYP1A2CYP2C19L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL31752186 | 0.84 | KDM4E (0.57) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508473-B1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | AIST (JP) | 2021-05-26 | — | — | EP | disclosed |
| US-10752579-B2 | Production method of carbamic acid ester | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3508473-A1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | National Institute of Advanced Industrial Science and Technology (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2019-06-20 | — | — | US | disclosed |
| CN-109641835-A | Method for producing carbamate | 国立研究开发法人产业技术综合研究所 | 2019-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185420-A1 | PRODUCTION METHOD OF CARBAMIC ACID ESTER | CA2, CA7, CA4 | SMN1; SMN2 3068/4885CYP1A2 926/4885CYP2C19 697/4885 |
| US-10752579-B2 | Production method of carbamic acid ester | CA2, CA7, CA4 | SMN1; SMN2 3068/4885CYP1A2 926/4885CYP2C19 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.